Tirzepatide was linked to improved weight loss outcomes in patients with PCOS, especially those who used a digital weight ...

Injectable weight-loss drugs can reduce the risk of serious cardiovascular events for people with type 2 diabetes.

ATLANTA — Tirzepatide appeared highly effective in reducing weight among women with polycystic ovary syndrome (PCOS) and overweight or obesity, real-world data from a retrospective analysis of over ...

CVOT, notable for comparing the two drugs, tirzepatide showed significantly greater improvements in major kidney outcomes vs dulaglutide.

New research from the Technical University of Munich and Harvard Medical School reveals that popular GLP-1-based drugs, ...

More than 90% of women with polycystic ovary syndrome achieved at least 10% total weight loss after 10 months of tirzepatide ...

Tirzepatide's dual mechanism targets GIP and GLP-1, so it provides strong cardiovascular benefits, said Stephen Nicholls, ...

A new database study has found that the injectable weight-loss drugs semaglutide and tirzepatide significantly reduce the ...

An IV infusion clinic in Cullman has been court ordered to temporarily close its doors after being accused of administering ...

A prespecified analysis of the SURPASS-CVOT trial assessed the efficacy and safety of tirzepatide compared with dulaglutide on kidney outcomes in patients with very high-risk CKD and type 2 diabetes.

Mass General Brigham researchers used real-world data to conduct a head-to-head study to investigate cardioprotective effects, finding both medications reduced risk ...

GLP-1 drugs tirzepatide and semaglutide may offer increased protection against heart attack, stroke and death from any cause, according to a November study published in Nature Medicine and presented ...